Literature DB >> 25164058

Recent advances in the development of anti-infective prophylactic and/or therapeutic agents based on Toll-Like Receptor (TLRs).

Elena C Junquera, Lourdes Mateos-Hernández, Jose de la Fuente, Jose M P de la Lastra1.   

Abstract

Toll-like receptors (TLRs) are key players in innate immunity. They are able to sense different microorganisms ranging from protozoa to bacteria, fungi or viruses. Innate immune responses can directly influence adaptive immune responses. Therefore, TLRs are considered as relevant targets for therapeutic applications in immune diseases: such as autoimmune disorders, allergy, sepsis, and cancer. We here review the recent patents based on the modulation of the toll-like receptors to develop anti-infective (prophylactic and/or therapeutic) agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25164058     DOI: 10.2174/1574891x09666140616164918

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  3 in total

1.  Neutrophils Contribute to the Protection Conferred by ArtinM against Intracellular Pathogens: A Study on Leishmania major.

Authors:  Rafael Ricci-Azevedo; Aline Ferreira Oliveira; Marina C A V Conrado; Fernanda Caroline Carvalho; Maria Cristina Roque-Barreira
Journal:  PLoS Negl Trop Dis       Date:  2016-04-08

Review 2.  A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies.

Authors:  Raj K Singh; Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Ashok Munjal; Sandip K Khurana; Sandip Chakraborty; Yashpal S Malik; Nitin Virmani; Rajendra Singh; Bhupendra N Tripathi; Muhammad Munir; Johannes H van der Kolk
Journal:  Front Microbiol       Date:  2018-09-06       Impact factor: 5.640

3.  CD14 is critical for TLR2-mediated M1 macrophage activation triggered by N-glycan recognition.

Authors:  Thiago Aparecido da Silva; André L V Zorzetto-Fernandes; Nerry T Cecílio; Aline Sardinha-Silva; Fabrício Freitas Fernandes; Maria Cristina Roque-Barreira
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.